Kineta’s dalazatide (formerly ShK-186) has a mechanism of action broad enough to treat many autoimmune diseases

Stuart SchlossmanMS Research Study and Reports

Grant Awards

Kineta’s Autoimmune Program is supported by the National Institute of Health.
DEVELOPMENT OF KV1.3 CHANNEL BLOCKER SHK-186 AS A THERAPY FOR MULTIPLE SCLEROSIS
1R43AI085691-01
PI: Shawn P. Iadonato
Listed as: Funding Mechanism, Title, Application #, Collaborators (if any)

Read more, here

~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT with MS Views and News – OPT-IN here
.
.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews